Research Achievements

Scientific Articles

2014


A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer


N. Masuda · K. Higaki · T. Takano · N. Matsunami · T. Morimoto · S. Ohtani · M. Mizutani · T. Miyamoto · K. Kuroi · S. Ohno · S. Morita · M. Toi


Cancer Chemotherapy and Pharmacology. (2014 Aug) 74(2):229-38. doi: 10.1007/s00280-014-2492-y

Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)


M. Takada, H. Ishiguro, S. Nagai, S. Ohtani, H. Kawabata, Y. Yanagita, Y. Hozumi, C. Shimizu, S. Takao, N. Sato, Y. Kosaka, Y. Sagara, H. Iwata, S. Ohno, K. Kuroi, N. Masuda, H. Yamashiro, M. Sugimoto, M. Kondo, Y. Naito,H. Sasano, T. Inamoto, S. Morita, & M. Toi on behalf of the JBCRG-C03 Collaborative Group


Breast Cancer Research and Treatment 2014 May;145(1):143-53. doi: 10.1007/s10549-014-2907-9.

Scientific Articles
by Voluntary Organization JBCRG